Related Experiment Video
Updated: May 16, 2026
Neurodevelopmental Reflex Testing in Neonatal Rat Pups
Published on: April 24, 2017
Dexamethasone administration to the neonatal rat results in neurological dysfunction at the juvenile stage even at
Yuko Ichinohashi1, Yoshiaki Sato, Akiko Saito
1Division of Obstetrics and Gynecology, Aichi Medical University Graduate School of Medicine, Nagakute, Aichi 480-1195, Japan. yukoichi@poem.ocn.ne.jp
Insights
Dexamethasone (DEX) administration in premature infants may cause neurological dysfunction. This study found DEX impaired learning and reduced neural stem cell proliferation in neonatal rats, suggesting a link to developmental issues.
Area of Science:
- Neuroscience
- Developmental Biology
- Pharmacology
Background:
- Dexamethasone (DEX), a synthetic glucocorticoid, is used to treat premature infants, preventing conditions like chronic lung disease.
- Neurologic complications from DEX are reported, but its detailed effects on the developing brain are not fully understood.
Purpose of the Study:
- To investigate the impact of low-dose Dexamethasone on neural development and behavior in neonatal rats.
- To elucidate the cellular mechanisms underlying potential DEX-induced neurotoxicity.
Main Methods:
- Neonatal rats received daily low-dose Dexamethasone during the first postnatal week.
- Behavioral tests (shuttle avoidance) were conducted at the juvenile stage.
- Cellular analysis of hippocampal apoptosis and mitosis, and in vitro culture of neural stem/progenitor cells with DEX.
Main Results:
- DEX-treated rats showed reduced somatic and brain weights and exhibited learning disabilities.
- Hippocampal analysis revealed increased apoptosis and decreased mitosis in DEX-exposed rats.
- In vitro, DEX inhibited neural stem/progenitor cell growth without increasing cell death.
Conclusions:
- Low-dose Dexamethasone administration in neonatal rats impairs neural development and cognitive function.
- DEX appears to induce neurological dysfunction by inhibiting neural stem/progenitor cell proliferation.
- Findings suggest a potential risk of neurological complications in premature infants treated with Dexamethasone.
Abstract:
Dexamethasone (DEX), a synthetic glucocorticoid, has been widely used to prevent the development of a variety of poor health conditions in premature infants including chronic lung disease, inflammation, circulatory failure, and shock. Although there are some reports of neurologic complications related to DEX exposure, its full effects on the premature brain have not been examined in detail. To investigate the effects of DEX on neural development, we first administered low doses (0.2 mg/kg bodyweight or less) of the glucocorticoid to neonatal rats on a daily basis during the first postnatal week and examined subsequent behavioral alterations at the juvenile stage. DEX-treated rats exhibited not only a significant reduction in both somatic and brain weights but also learning disabilities as revealed in the shuttle avoidance test. The hippocampi of DEX-treated rats displayed a high apoptotic and a low mitotic cell density compared to control rats on day 7 after birth. In a subsequent experiment, neural stem/progenitor cells were cultured in the presence of DEX for 6 days. The glucocorticoid inhibited cell growth without an increase in cell death. These results suggest that administration of DEX to premature infants induces neurological dysfunction via inhibition of the proliferation of neural stem/progenitor cells.
